Class Action Challenging CVS Caremark’s Removal of Zepbound from Its Formulary
Follow to receive email when new source reporting is added to this case. Email delivery also depends on your profile notification settings and a verified email address.
CVS Caremark · Zepbound formulary coverage and pharmacy benefit management · Ongoing Litigation
Last updated
About this case
Users of Eli Lilly's Zepbound allege that CVS Caremark improperly removed the obesity treatment from its formulary after making Wegovy the preferred treatment, disputing CVS's position that the products were interchangeable. The matter is described as a class-action lawsuit, but its current procedural stage is not specified.
Case overview
- Defendant company
- CVS Caremark
- Product or service
- Zepbound formulary coverage and pharmacy benefit management
- Court case number
- 1:25-cv-07307
- Case status
- Ongoing Litigation
- Lawsuit type
- Consumer
- Reported harm
- Billing Fees
Participation information
Availability is based on each listed participation option and its deadline.
No active participation options are currently listed.
This information does not determine whether you qualify for a case.
Sources
Public reporting associated with this case.